Chronic kidney disease (CKD) is a long-term progressive disorder characterized by structural or functional abnormalities of the kidneys that persist for at least three months and result in a gradual decline in renal function.¹ The kidneys play a vital role in maintaining homeostasis by regulating fluid balance, electrolyte concentrations, acid-base equilibrium, blood pressure, and the excretion of metabolic waste products.² Impairment of these functions can lead to significant physiological disturbances, affecting multiple organ systems and contributing to increased morbidity and mortality worldwide.

CKD has emerged as a major global public health concern, affecting approximately 10–15% of the adult population worldwide.^3,4 The burden of the disease continues to rise due to increasing life expectancy, urbanization, and the growing prevalence of chronic conditions such as diabetes mellitus, hypertension, obesity, and cardiovascular diseases.⁵ According to international health reports, CKD is among the leading causes of death and disability-adjusted life years, imposing substantial economic and healthcare burdens on both developed and developing countries.⁶

The pathophysiology of CKD involves progressive nephron loss resulting from various etiological factors.^7,8 Diabetes mellitus remains the most common cause of CKD globally, followed by hypertension, glomerulonegfdand disturbances in electrolyte and hormonal regulation lead to complications such as anemia, mineral and bone disorders, cardiovascular disease, and end-stage renal disease (ESRD).

The diagnosis and staging of CKD are primarily based on the estimated glomerular filtration rate (eGFR) and evidence of kidney damage, including albuminuria or structural abnormalities.¹² Biomarkers such as serum creatinine, blood urea nitrogen (BUN), urinary protein excretion, and electrolyte levels are routinely used to assess renal function and monitor disease progression. Early stages of CKD are often asymptomatic, resulting in delayed diagnosis and treatment. Consequently, many patients present with advanced disease, where therapeutic interventions are less effective in preventing progression to kidney failure.

Recent advances in nephrology have emphasized the importance of early detection, risk factor modification, and multidisciplinary management approaches. Lifestyle interventions, glycemic and blood pressure control, renin–angiotensin–aldosterone system inhibition, and novel therapeutic agents such as sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated significant benefits in slowing disease progression and reducing cardiovascular complications. Nevertheless, CKD continues to pose significant clinical challenges, particularly in low- and middle-income countries where access to healthcare services, diagnostic facilities, and renal replacement therapies may be limited.

Given the increasing prevalence and serious health consequences of CKD, there is a critical need to evaluate the clinical and biochemical characteristics associated with the disease and to identify major risk factors contributing to renal dysfunction. Therefore, the present study was designed to investigate the prevalence of chronic kidney disease, assess alterations in renal biomarkers, and examine the relationship between demographic and clinical risk factors and kidney function impairment. Understanding these associations may contribute to improved preventive strategies, early diagnosis, and effective management of CKD, ultimately reducing disease burden and improving patient outcomes.

Study Design and Setting: A hospital-based cross-sectional observational study was conducted to evaluate the clinical and biochemical characteristics of patients with chronic kidney disease (CKD). The study was carried out in the Department of Nephrology and Clinical Biochemistry of a tertiary care teaching hospital over a period of six months. Study Population: A total of 200 participants were enrolled in the study, including 150 patients diagnosed with chronic kidney disease and 50 apparently healthy individuals who served as the control group. Participants were selected through convenient sampling after obtaining informed consent. Inclusion Criteria • Patients aged 18 years and above. • Diagnosed cases of chronic kidney disease according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. • Patients with documented renal impairment for at least three months. • Both male and female participants. Exclusion Criteria • Patients with acute kidney injury. • Individuals with active infections, malignancies, or severe liver disease. • Pregnant women. • Patients receiving renal transplantation. Data Collection Demographic and clinical information, including age, gender, body mass index (BMI), smoking status, medical history, duration of disease, presence of hypertension, diabetes mellitus, and medication use, were recorded using a structured questionnaire and patient medical records. Sample Collection and Biochemical Analysis Approximately 5 mL of venous blood was collected from each participant under aseptic conditions. Blood samples were centrifuged, and serum was separated for biochemical analysis. Early morning urine samples were also collected for proteinuria assessment. The following parameters were measured: • Serum creatinine • Blood urea nitrogen (BUN) • Uric acid • Estimated glomerular filtration rate (eGFR) • Serum sodium, potassium, and chloride • Hemoglobin concentration • Urinary protein excretion Serum creatinine, BUN, uric acid, and electrolytes were analyzed using an automated biochemical analyzer. Hemoglobin levels were measured using a hematology analyzer. eGFR was calculated using the CKD-EPI equation. Outcome Measures The primary outcomes included assessment of renal function markers (serum creatinine, BUN, and eGFR) and identification of major risk factors associated with CKD. Secondary outcomes included evaluation of anemia, electrolyte imbalance, and proteinuria among CKD patients. Statistical Analysis Data were entered and analyzed using Statistical Package for Social Sciences (SPSS) version 26.0. Continuous variables were expressed as mean ± standard deviation (SD), while categorical variables were presented as frequencies and percentages. Comparisons between CKD patients and healthy controls were performed using the Student’s t-test for continuous variables and the Chi-square test for categorical variables. One-way analysis of variance (ANOVA) was used to compare biochemical parameters across different stages of CKD. A p-value of less than 0.05 was considered statistically significant.

A total of 200 participants were included in the study, comprising 150 patients with chronic kidney disease (CKD) and 50 healthy controls. The mean age of CKD patients was significantly higher than that of the control group. Hypertension and diabetes mellitus were the most prevalent comorbid conditions among CKD patients. Significant alterations in renal biomarkers, hematological parameters, and electrolyte levels were observed in CKD patients compared to healthy controls.

Table 1. Demographic and Clinical Characteristics of Study Participants

Interpretation: Hypertension and diabetes mellitus were significantly more prevalent among CKD patients than controls, indicating their strong association with kidney disease.

Table 2. Comparison of Biochemical Parameters Between CKD Patients and Controls

Interpretation: CKD patients demonstrated significantly elevated serum creatinine, blood urea nitrogen, uric acid, potassium levels, and urinary protein excretion, while eGFR and sodium levels were significantly reduced.

Table 3. Hematological Parameters and CKD Staging

Chronic kidney disease (CKD) is a progressive disorder associated with significant biochemical, hematological, and metabolic abnormalities that adversely affect patient health and quality of life. The present study evaluated the clinical characteristics and laboratory findings among CKD patients and demonstrated substantial deterioration in renal function parameters compared with healthy controls. The findings highlight the importance of early diagnosis and management of risk factors to prevent disease progression and associated complications. The demographic analysis revealed that CKD was more common among older individuals, consistent with previous studies reporting age as an important risk factor for renal impairment. Aging is associated with a gradual decline in nephron number, reduced glomerular filtration rate, and increased susceptibility to chronic diseases such as hypertension and diabetes mellitus, which contribute to kidney damage. The higher body mass index observed among CKD patients further supports the role of obesity as a contributing factor in the development and progression of renal disease. In the present study, hypertension and diabetes mellitus emerged as the most prevalent comorbid conditions among CKD patients. These findings are in agreement with global epidemiological reports identifying diabetic nephropathy and hypertensive nephrosclerosis as the leading causes of CKD. Persistent hyperglycemia promotes glomerular hyperfiltration, oxidative stress, and fibrosis, while uncontrolled hypertension accelerates vascular and glomerular injury. The coexistence of these conditions substantially increases the risk of progressive renal dysfunction and end-stage renal disease. Biochemical analysis demonstrated significantly elevated serum creatinine and blood urea nitrogen (BUN) levels among CKD patients. These biomarkers are widely recognized indicators of impaired renal filtration and reduced excretory function. As nephron loss progresses, the kidneys become less efficient at eliminating metabolic waste products, resulting in their accumulation in the bloodstream. The marked reduction in estimated glomerular filtration rate (eGFR) observed in CKD patients further confirms the presence of substantial renal impairment and serves as an important indicator of disease severity. Proteinuria was significantly increased among CKD patients and showed a progressive rise with advancing disease stages. Proteinuria is considered both a marker and mediator of kidney damage. Increased urinary protein excretion reflects disruption of the glomerular filtration barrier and is associated with ongoing inflammation, tubular injury, and fibrosis. Numerous studies have demonstrated that the degree of proteinuria correlates strongly with the rate of CKD progression and cardiovascular risk. Electrolyte abnormalities were also evident in the study population. CKD patients exhibited significantly lower serum sodium levels and higher potassium concentrations compared with healthy controls. These findings reflect impaired tubular function and reduced renal capacity to maintain electrolyte and fluid homeostasis. Hyperkalemia is particularly important because it can lead to serious cardiac complications, including arrhythmias and sudden cardiac death, especially in patients with advanced renal failure. The present study also identified anemia as a common complication of CKD, with hemoglobin levels declining significantly across advancing disease stages. Anemia in CKD primarily results from decreased erythropoietin production by damaged renal tissue, although iron deficiency, chronic inflammation, and shortened red blood cell survival may also contribute. The progressive reduction in hemoglobin concentration observed in Stage 4 and Stage 5 CKD patients is consistent with previous reports and highlights the importance of regular hematological monitoring and timely therapeutic intervention. A significant trend of worsening biochemical and hematological parameters was observed from Stage 3 to Stage 5 CKD. Serum creatinine, BUN, and proteinuria increased progressively, whereas eGFR and hemoglobin levels declined. These findings confirm the progressive nature of CKD and emphasize the need for early detection and intervention before irreversible kidney damage occurs. Effective management of hypertension, diabetes, proteinuria, and anemia may slow disease progression and improve patient outcomes. Despite providing valuable insights, the study has certain limitations. The cross-sectional design limits the ability to establish causal relationships between risk factors and disease progression. Additionally, the study was conducted at a single center with a relatively limited sample size, which may affect the generalizability of the findings. Future multicenter longitudinal studies involving larger populations and additional biomarkers are recommended to better understand the mechanisms underlying CKD progression and to identify novel therapeutic targets.

The present study concludes that chronic kidney disease (CKD) is a progressive and multifactorial disorder associated with significant deterioration of renal function, accompanied by substantial biochemical, hematological, and electrolyte abnormalities. Elevated serum creatinine, blood urea nitrogen, proteinuria, and potassium levels, along with reduced estimated glomerular filtration rate and hemoglobin concentrations, were strongly associated with disease progression. Hypertension and diabetes mellitus were identified as the most prevalent and influential risk factors contributing to the development and advancement of CKD. Furthermore, the severity of renal impairment increased markedly across different stages of the disease, emphasizing the progressive nature of CKD and its impact on overall health. These findings highlight the importance of early detection, routine screening of high-risk individuals, effective control of modifiable risk factors, and regular monitoring of renal biomarkers to delay disease progression, reduce complications, and improve the quality of life and long-term prognosis of patients with chronic kidney disease.

1. Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M, Massy Z, Wanner C, Anders HJ. Chronic kidney disease. Nature reviews Disease primers. 2017 Nov 23;3(1):17088.
2. Madhavan Unny N, Zarina A, Beena V. Fluid and electrolyte balance. InTextbook of Veterinary Physiology 2023 Sep 1 (pp. 193-211). Singapore: Springer Nature Singapore.
3. Francis A, Harhay MN, Ong AC, Tummalapalli SL, Ortiz A, Fogo AB, Fliser D, Roy-Chaudhury P, Fontana M, Nangaku M, Wanner C. Chronic kidney disease and the global public health agenda: an international consensus. Nature Reviews Nephrology. 2024 Jul;20(7):473-85.
4. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney international supplements. 2022 Apr 1;12(1):7-11.
5. Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. InRenal fibrosis: mechanisms and therapies 2019 Aug 9 (pp. 3-15). Singapore: Springer Singapore.
6. Francis A, Harhay MN, Ong AC, Tummalapalli SL, Ortiz A, Fogo AB, Fliser D, Roy-Chaudhury P, Fontana M, Nangaku M, Wanner C. Chronic kidney disease and the global public health agenda: an international consensus. Nature Reviews Nephrology. 2024 Jul;20(7):473-85.
7. Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. Nature Reviews Nephrology. 2020 May;16(5):269-88.
8. Agarwal A, Nath KA. Pathophysiology of chronic kidney disease progression: organ and cellular considerations. InChronic renal disease 2020 Jan 1 (pp. 263-278). Academic Press.
9. Hoogeveen EK. The epidemiology of diabetic kidney disease. Kidney and Dialysis. 2022 Aug 1;2(3):433-42.
10. Li H, Lu W, Wang A, Jiang H, Lyu J. Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from Global Burden of Disease 2017. Journal of diabetes investigation. 2021 Mar;12(3):346-56.
11. Hoogeveen EK. The epidemiology of diabetic kidney disease. Kidney and Dialysis. 2022 Aug 1;2(3):433-42.
12. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. Jama. 2019 Oct 1;322(13):1294-304.

1. Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M, Massy Z, Wanner C, Anders HJ. Chronic kidney disease. Nature reviews Disease primers. 2017 Nov 23;3(1):17088.
2. Madhavan Unny N, Zarina A, Beena V. Fluid and electrolyte balance. InTextbook of Veterinary Physiology 2023 Sep 1 (pp. 193-211). Singapore: Springer Nature Singapore.
3. Francis A, Harhay MN, Ong AC, Tummalapalli SL, Ortiz A, Fogo AB, Fliser D, Roy-Chaudhury P, Fontana M, Nangaku M, Wanner C. Chronic kidney disease and the global public health agenda: an international consensus. Nature Reviews Nephrology. 2024 Jul;20(7):473-85.
4. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney international supplements. 2022 Apr 1;12(1):7-11.
5. Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. InRenal fibrosis: mechanisms and therapies 2019 Aug 9 (pp. 3-15). Singapore: Springer Singapore.
6. Francis A, Harhay MN, Ong AC, Tummalapalli SL, Ortiz A, Fogo AB, Fliser D, Roy-Chaudhury P, Fontana M, Nangaku M, Wanner C. Chronic kidney disease and the global public health agenda: an international consensus. Nature Reviews Nephrology. 2024 Jul;20(7):473-85.
7. Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. Nature Reviews Nephrology. 2020 May;16(5):269-88.
8. Agarwal A, Nath KA. Pathophysiology of chronic kidney disease progression: organ and cellular considerations. InChronic renal disease 2020 Jan 1 (pp. 263-278). Academic Press.
9. Hoogeveen EK. The epidemiology of diabetic kidney disease. Kidney and Dialysis. 2022 Aug 1;2(3):433-42.
10. Li H, Lu W, Wang A, Jiang H, Lyu J. Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from Global Burden of Disease 2017. Journal of diabetes investigation. 2021 Mar;12(3):346-56.
11. Hoogeveen EK. The epidemiology of diabetic kidney disease. Kidney and Dialysis. 2022 Aug 1;2(3):433-42.
12. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. Jama. 2019 Oct 1;322(13):1294-304.